Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma.

Katsuya H, Cook LBM, Rowan AG, Satou Y, Taylor GP, Bangham CRM.

Biomark Res. 2018 Jul 18;6:24. doi: 10.1186/s40364-018-0138-7. eCollection 2018.

2.

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.

Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner CM, Klein C, Liu N, Hallek M, Frenzel LP, Krause G.

Int J Cancer. 2015 Nov 1;137(9):2234-42. doi: 10.1002/ijc.29579. Epub 2015 May 12.

3.

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.

Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S.

Blood. 2019 Aug 8;134(6):534-547. doi: 10.1182/blood.2018881029. Epub 2019 Apr 22.

PMID:
31010847
4.

PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

Lampson BL, Brown JR.

Expert Opin Investig Drugs. 2017 Nov;26(11):1267-1279. doi: 10.1080/13543784.2017.1384815. Epub 2017 Oct 6. Review.

5.

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.

Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V.

Clin Cancer Res. 2015 Apr 1;21(7):1537-42. doi: 10.1158/1078-0432.CCR-14-2034. Epub 2015 Feb 10. Review.

6.

Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines.

Ishikawa C, Senba M, Mori N.

Oncol Lett. 2018 Apr;15(4):5311-5317. doi: 10.3892/ol.2018.7979. Epub 2018 Feb 7.

7.

Idelalisib may have the potential to increase radiotherapy side effects.

Gryc T, Putz F, Goerig N, Ziegler S, Fietkau R, Distel LV, Schuster B.

Radiat Oncol. 2017 Jun 28;12(1):109. doi: 10.1186/s13014-017-0827-7.

8.

Activation of hypoxia-inducible factor 1 in human T-cell leukaemia virus type 1-infected cell lines and primary adult T-cell leukaemia cells.

Tomita M, Semenza GL, Michiels C, Matsuda T, Uchihara JN, Okudaira T, Tanaka Y, Taira N, Ohshiro K, Mori N.

Biochem J. 2007 Sep 1;406(2):317-23. Retraction in: Biochem J. 2011 Mar 15;434(3):571.

9.

JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells.

Yamada O, Ozaki K, Akiyama M, Kawauchi K.

Mol Cancer Ther. 2012 May;11(5):1112-21. doi: 10.1158/1535-7163.MCT-11-0850. Epub 2012 Mar 8.

10.

The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.

Brown JR.

Semin Oncol. 2016 Apr;43(2):260-4. doi: 10.1053/j.seminoncol.2016.02.004. Epub 2016 Feb 8. Review.

PMID:
27040704
11.

New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.

Hales EC, Taub JW, Matherly LH.

Cell Signal. 2014 Jan;26(1):149-61. doi: 10.1016/j.cellsig.2013.09.021. Epub 2013 Oct 16. Review.

PMID:
24140475
12.

Activation of PKC-δ in HTLV-1-infected T cells.

Mori N, Ishikawa C, Senba M.

Int J Oncol. 2015 Apr;46(4):1609-18. doi: 10.3892/ijo.2015.2848. Epub 2015 Jan 26.

PMID:
25625567
13.

Adult T-cell leukemia/lymphoma in Jamaica and its relationship to human T-cell leukemia/lymphoma virus type I-associated lymphoproliferative disease.

Gibbs WN, Lofters WS, Campbell M, Hanchard B, LaGrenade L, Clark J, Cranston B, Saxinger C, Gallo R, Blattner WA.

Princess Takamatsu Symp. 1984;15:77-90.

PMID:
6100652
14.

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ.

Blood. 2010 Sep 23;116(12):2078-88. doi: 10.1182/blood-2010-02-271171. Epub 2010 Jun 3.

15.

Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.

Taniguchi H, Hasegawa H, Sasaki D, Ando K, Sawayama Y, Imanishi D, Taguchi J, Imaizumi Y, Hata T, Tsukasaki K, Uno N, Morinaga Y, Yanagihara K, Miyazaki Y.

Cancer Sci. 2014 Dec;105(12):1601-8. doi: 10.1111/cas.12540. Epub 2014 Nov 5.

16.

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis.

Horak F, Puri KD, Steiner BH, Holes L, Xing G, Zieglmayer P, Zieglmayer R, Lemell P, Yu A.

J Allergy Clin Immunol. 2016 Jun;137(6):1733-1741. doi: 10.1016/j.jaci.2015.12.1313. Epub 2016 Feb 23.

PMID:
26915677
17.

YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells.

Sasaki R, Ito S, Asahi M, Ishida Y.

Leuk Res. 2015 Dec;39(12):1473-9. doi: 10.1016/j.leukres.2015.10.012. Epub 2015 Oct 27.

PMID:
26547260
18.

The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.

Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA.

PLoS One. 2013 Dec 23;8(12):e83830. doi: 10.1371/journal.pone.0083830. eCollection 2013.

19.

Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.

Yang Q, Chen LS, Ha MJ, Do KA, Neelapu SS, Gandhi V.

Clin Cancer Res. 2017 Jan 1;23(1):181-192. doi: 10.1158/1078-0432.CCR-15-3135. Epub 2016 Jun 24.

20.

Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Barrientos JC.

Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21. Review.

PMID:
27324214

Supplemental Content

Support Center